💊 Drugs A-Z 🧬 Targets 🛠 Tools 📚 Guides
All Drugs Drug Classes Therapeutic Areas Side Effects
Guides Glossary Timeline
Comparisons Drug Journeys Drug Families
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Talquetamab

CHEMBL4594503 Phase 4 Approved Antibody
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

Talquetamab is a bispecific T-cell engager antibody that simultaneously binds to GPRC5D on multiple myeloma cells and CD3 on T cells, redirecting cytotoxic T cells to kill tumor cells. It is approved for relapsed or refractory multiple myeloma after multiple prior lines of therapy, and is under investigation for leukemia. Its target, GPRC5D, is highly expressed on myeloma cells and plasma cells, providing a selective therapeutic window.

Therapeutic Areas

Leukemia Lymphoma Oncology

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Frequently Asked Questions

Talquetamab is a bispecific T-cell engager antibody that simultaneously binds to GPRC5D on multiple myeloma cells and CD3 on T cells, redirecting cytotoxic T cells to kill tumor cells. It is approved for relapsed or refractory multiple myeloma after multiple prior lines of therapy, and is under investigation for leukemia. Its target, GPRC5D, is highly expressed on myeloma cells and plasma cells, providing a selective therapeutic window.

Yes, Talquetamab is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4594503. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-08-20.

Medical Disclaimer

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.